Mabpharm (HKG:2181) shrank its attributable loss in 2024 by 39% to 127.9 million yuan from the 209.4 million yuan loss in the year-ago period, a Wednesday filing with the Hong Kong bourse said.
Loss per share stood at 0.03 yuan, compared with 0.05 yuan loss per share in 2023.
The biopharmaceutical firm's revenue for the year increased by 196% to 258.2 million yuan from 87.2 million yuan a year prior.
The higher revenue was mainly due to the launch of CMAB009 in the market, higher sales of CMAB007 and CMAB008, and a boost in revenue from the exclusive right for commercialization and contract development and manufacturing agreement of CMAB806.
The firm attributed the shrinking of loss mainly to an increase in gross profit, as well as lower research and development expenses.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。